Michael Jirousek - Catabasis Pharmaceuticals Insider

CATB -- USA Stock  

USD 1.34  0.32  31.37%

Co-Founder and Member of Scientific Advisory Board

Dr. Michael Jirousek, Ph.D. is the CoFounder and Chief Scientific Officer of Catabasis Pharmaceuticals, Inc. He has more than twenty years of experience in pharmaceutical research and development. Prior to joining the Company, he was a Corporationrationrate Officer and Senior Vice President of research at Sirtris Pharmaceuticals, where he was Head of Research for the company. He joined Sirtris from Pfizer La Jolla, part of Pfizer Global Research and Development, where he was Senior Director and Head of the Metabolic Therapeutic Area. He founded the La Jolla group. Prior to joining Pfizer, he was the Department Head at Abbott Laboratories for three years. He spent eight years at Eli Lilly in Indianapolis and Hamburg, Germany, focusing on diabetic complications and PKC inhibitors
Age: 55  Founder Since 2008  Ph.D    
617-349-1971  http://www.catabasis.com
Jirousek holds a Ph.D. in chemistry from Case Western Reserve University and was a postdoctoral fellow at Harvard University and holds a Ph.D. in Chemistry from Case Western University and a B.S. in Chemistry from Kent State University.

Management Efficiency

The company has return on total asset (ROA) of (65.2) % which means that it has lost $65.2 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (147.16) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 1.66 M in liabilities with Debt to Equity (D/E) ratio of 12.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Catabasis Pharmaceuticals has Current Ratio of 3.33 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted linker drug discovery platform in the United States. The company was founded in 2008 and is based in Cambridge, Massachusetts. Catabasis Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ General Markets. It employs 36 people.Catabasis Pharmaceuticals (CATB) is traded on NASDAQ General Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 36 people. Catabasis Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Catabasis Pharmaceuticals Leadership Team

Jean George, Director, MBA
Angelika Fretzen, President, MBA
Rick Modi, Executive, MBA
Joanne Donovan, Executive, Ph.D
Deirdre Cunnane, President
Michael Jirousek, Founder, Ph.D
Michael Kishbauch, Director, MBA
Edward Hibben, Executive, MBA
Ian Sanderson, CFO, MBA
Burt Adelman, Director, Ph.D
Deirdre JD, SVP
Kenneth Bate, Director, MBA
Jill Milne, CEO, Ph.D
Andrea Matthews, Executive
Nicholas Galakatos, Director, Ph.D
Ron Laufer, Director, MBA
Michael Ross, Chairman, Ph.D
Andrew Nichols, SVP, Ph.D
Ted Hibben, SVP, MBA

Stock Performance Indicators

Did you try this?

Run Performance Analysis Now
   

Performance Analysis

Check effects of mean-variance optimization against your current asset allocation
All  Next Launch Performance Analysis

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Catabasis Pharmaceuticals and NantKwest. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.